ABL1 and melanoma: In summary, these exciting data indicate that targeting ABL1/2 and DDR1 in combination with MEKi may be an effective therapeutic regimen for patients with aggressive NRAS-driven melanomas, who have a poor prognosis and limited therapeutic options.